![laminas multipanel laminas multipanel](https://comeca.com.mx/wp-content/uploads/2019/03/que-es-el-multipanel-usos.jpg)
![laminas multipanel laminas multipanel](http://casetasgrupomonterrey.com.mx/img/MULTYPANEL-2.jpg)
TAAs in breast cancer patients may be useful for early detection. Logistic analysis showed that seropositivity (positive for one or more TAAs) in breast cancer patients was independent from any TNM factor or disease stage and was significantly associated with histological grade in the multivariate analysis (p = 0.007). The positivity rate was significantly higher for the non‐luminal type than for the luminal type (p = 0.003). Even in the stage 0/I patients, 24% showed that two or more TAAs were positive, and the positive rate of a five‐TAA combination assay was 37%. The positive rates of all TAAs of stage 0/I were similar to those of all patients. The positive TAA rates were relatively high for p53 (10%) and RalA (10%). Sera from 73 healthy donors and 386 patients with breast cancer, including 182 stage 0/I patients, were evaluated by using cutoff values for each TAA equal to the mean +3 SDs of the serum levels of healthy controls. Seventeen recombinant proteins with tags in Escherichia coli (p53, RalA, p90, NY‐ESO‐1, HSP70, c‐myc, galectin‐1, Sui1, KN‐HN‐1, HSP40, PrxVI, p62, cyclin B1, HCC‐22‐5, annexin II, HCA25a, and HER2) were applied as capturing antigens in sandwich ELISA to measure serum IgG levels. Since the production of tumor‐associated antibodies (TAAs) is considered to be a humoral immune response in cancer patients, serum autoantibodies may be detected even in patients with early stage tumors. Such high positive rates will be helpful for detecting colorectal cancer regardless of tumor stages. The combination assay of six tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, and NY-ESO-1) achieved a positive rate of 56%. The measurement of set of 17 autoantibodies allowed autoantibody profiling in patients with colorectal cancer. Moreover, these autoantibodies showed relatively high positive rates even during stage 0/I disease (55 and 70% with 6 and 17 antibodies, respectively). Positive rates of 56, 62, 66, 71, and 73% were obtained with 6, 9, 11, 14, and 17 antibodies, respectively, for the overall disease.
![laminas multipanel laminas multipanel](https://laminas.com.mx/wp-content/uploads/2021/02/panel-multymuro-300x138.png)
Combination assays using multiple autoantibodies increased the positive rates based on the number of autoantibodies used. Cutoff values were fixed at mean + 3 standard deviations of serum titers in healthy controls.Īutoantibodies with the highest positive rates were p53 (20%), RalA (14%), HSP70 (12%), and Galectin1 (11%). Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer.Īutoantibodies against 17 tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, NY-ESO-1, p90, Sui1, HSP40, CyclinB1, HCC-22-5, c-myc, PrxVI, VEGF, HCA25a, p62, and Annexin II) were evaluated in 279 patients with colorectal cancer and 74 healthy controls. Although serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%.